2021 World Conference on Lung Cancer (Posters)-FP16. Early Circulating-Tumor DNA EGFR Mutation Clearance in Plasma as a Predictor of Clinical Outcomes in The AURA3 Trial

FP16. Early Circulating-Tumor DNA EGFR Mutation Clearance in Plasma as a Predictor of Clinical Outcomes in The AURA3 Trial

Back to course

Video Transcription

Video Summary

The speaker presented the results of a study on the use of Osmoletinib, an oral EGFR TTI, as a first-line treatment for EGFR mutant advanced non-small cell lung cancer. The study compared Osmoletinib with platinum chemotherapy and found that Osmoletinib was more effective. The study also explored the clearance of EGFR mutation circulating tumor DNA (CTDNA) at week three and six and its association with clinical outcomes. The analysis showed that patients with undetectable CTDNA at baseline had longer progression-free survival (PFS). Clearance of CTDNA at week three and six was associated with better response rates and longer PFS. The findings suggest that early CTDNA profiling can help predict treatment benefit in EGFR mutant advanced non-small cell lung cancer.

Asset Subtitle

Myung-Ju Ahn

Meta Tag

Speaker Myung-Ju Ahn

Topic Tumor Biology and Systems Biology: Basic and Translational Science

Keywords

Osmoletinib

EGFR mutant

non-small cell lung cancer

CTDNA

progression-free survival